Last reviewed · How we verify
NCT06159062
A Clinical Study of 162 in Subjects With Chronic Hepatitis B Virus Infection
Phase 1 trial testing 162 in Chronic Hepatitis B Virus Infection in 1 participant. Terminated before completion.
9 July 2024
Quick facts
| Lead sponsor | Yangshengtang Co., Ltd |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 1 |
| Start date | 3 June 2024 |
| Primary completion | 9 July 2024 |
| Estimated completion | 9 July 2024 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- 162
- Placebo
Conditions studied
- Chronic Hepatitis B Virus Infection — all drugs for Chronic Hepatitis B Virus Infection →
Sponsor
Yangshengtang Co., Ltd
Who can join
Adults 18 to 65, any sex, with Chronic Hepatitis B Virus Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this intervention research is to learn about the safety and tolerability of 162 with a single ascending dose in subjects with chronic hepatitis B virus (HBV) infection.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The significance of antibody to hepatitis B surface antigen in infection and clearance of hepatitis B virus.
Ding L, Huang J, Huang S. · · 2025 · cited 3× · PMID 39754388 · DOI 10.1080/21645515.2024.2445283
Verify or expand the search:
- PubMed search for NCT06159062
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of 162
Trials testing the same drug.
- NCT05310487 — Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects · Phase 1 · completed
Other recruiting trials for Chronic Hepatitis B Virus Infection
Currently open trials in the same condition.
- NCT07389044 — A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B · Phase 1 · recruiting
- NCT06537414 — A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living Wit · Phase 2 · active not recruiting
Other Yangshengtang Co., Ltd trials
Trials by the same sponsor.
- NCT05310487 — Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06159062 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yangshengtang Co., Ltd
- Last refreshed: 16 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06159062.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing